GILEAD SCIENCES, INC.
For the period ended Sep 30, 2026. Filed Oct 30, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2026 · Filed Oct 30, 2026
GILD$170.87+0.9%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Balance Sheets
| (in millions, except per share amounts) | September 30, 2026 | December 31, 2025 |
|---|---|---|
| Assets | ||
| Current assets: | ||
| Cash and cash equivalents | $6,437 | $7,564 |
| Short-term marketable debt securities | — | 68 |
| Accounts receivable, net | 5,007 | 4,913 |
| Inventories | 1,896 | 1,774 |
| Prepaid and other current assets | 3,214 | 4,024 |
| Total current assets | 16,553 | 18,342 |
| Property, plant and equipment, net | 5,945 | 5,606 |
| Long-term marketable debt securities | — | 2,974 |
| Intangible assets, net | 13,424 | 16,978 |
| Goodwill | 8,314 | 8,314 |
| Deferred tax assets | 2,270 | 1,964 |
| Other long-term assets | 4,902 | 4,845 |
| Total assets | $51,408 | $59,023 |
| Liabilities and Stockholders’ Equity | ||
| Current liabilities: | ||
| Accounts payable | $934 | $715 |
| Accrued rebates | 4,624 | 4,337 |
| Current portion of long-term debt, net | 2,416 | 2,807 |
| Other current liabilities | 4,028 | 3,953 |
| Total current liabilities | 12,002 | 11,813 |
| Long-term debt, net | 23,815 | 22,129 |
| Long-term income taxes payable | 974 | 896 |
| Deferred tax liabilities | 318 | 402 |
| Other long-term liabilities | 1,343 | 1,165 |
| Commitments and contingencies (Note 10) | ||
| Stockholders’ equity: | ||
| Preferred stock, par value $0.001 per share; 5 shares authorized; none outstanding | — | — |
| Common stock, par value $0.001 per share; 5,600 shares authorized; 1,241 shares issued and outstanding | 1 | 1 |
| Additional paid-in capital | 9,841 | 8,932 |
| Accumulated other comprehensive income | 89 | 39 |
| Retained earnings | 3,107 | 13,730 |
| Total Gilead stockholders’ equity | 13,040 | 22,703 |
| Noncontrolling interest | (84) | (84) |
| Total stockholders’ equity | 12,955 | 22,618 |
| Total liabilities and stockholders’ equity | $51,408 | $59,023 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.